EUVIMEDEUVIMED entdecken
Crossref

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction

Dhirendra K Simanshu iD, Rui Xu iD, James P Stice iD, Daniel J Czyzyk iD, Siyu Feng iD, John-Paul Denson iD, Erin Riegler iD, Yue Yang iD, Cathy Zhang, Sofia Donovan iD, Brian P Smith, Maria Abreu-Blanco iD und 29 weitere

Science · 24.07.2025 · 389 (6758) · 409-415

DOI: 10.1126/science.adq2004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 24.07.2025. Verfasst von Dhirendra K Simanshu und 40 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Institute (NCI) RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedi…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Class I Phosphatidylinositol 3-Kinases, Neoplasms, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BBO-10203 is an orally available drug that covalently and specifically binds to the rat sarcoma (RAS)–binding domain of phosphoinositide 3-kinase α (PI3Kα), preventing its activation by HRAS, NRAS, and KRAS. It inhibited PI3Kα activation in tumors with oncogenic mutations in KRAS or PIK3CA and in tumors with human epidermal growth factor receptor 2 (HER2) amplification or overexpression. In preclinical models, BBO-10203 caused significant tumor growth inhibition across multiple tumor types and showed enhanced efficacy in combination with inhibitors of cyclin-dependent kinase 4/6 (CDK4/6), estrogen receptor (ER), HER2, and KRAS-G12C mutant, including in tumors harboring mutations in Kelch-like ECH-associated protein 1 (KEAP1) and serine/threonine kinase 11 (STK11). Notably, these antitumor effects occurred without inducing hyperglycemia, because insulin signaling does not depend on RAS-mediated PI3Kα activation to promote glucose uptake.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsClass I Phosphatidylinositol 3-KinasesNeoplasmsPhosphoinositide-3 Kinase Inhibitorsras ProteinsAnimalsFemaleHumansMiceRatsCell Line, TumorGlucoseHyperglycemiaMice, NudeMutationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Signal TransductionHEK293 CellsXenograft Model Antitumor AssaysMCF-7 CellsThiazoles

Substanzen

AlpelisibAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesGlucosePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPIK3CA protein, humanProto-Oncogene Proteins p21(ras)ras ProteinsThiazoles

Autor:innen und Institutionen

  • National Cancer Institute (NCI) RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA.
  • BridgeBio Oncology Therapeutics, South San Francisco, CA, USA.
  • Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Massachusetts General Hospital Cancer Center, Boston, MA, USA, and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • BridgeBio Pharma, San Francisco, CA, USA.

ORCID-Profile: Dhirendra K Simanshu, Rui Xu, James P Stice, Daniel J Czyzyk, Siyu Feng, John-Paul Denson, Erin Riegler, Yue Yang, Sofia Donovan, Maria Abreu-Blanco, Cindy Feng, Lijuan Fu, Dana Rabara, Lucy C Young, Marcin Dyba, Wupeng Yan, Ken Lin, Samar Ghorbanpoorvalukolaie, Erik K Larsen, Wafa Malik, Allison Champagne, Jin Hyun Ju, Stevan Jeknic, Dominic Esposito, David M Turner, Felice C Lightstone, Bin Wang, Paul M Wehn, Andrew G Stephen, Aaron N Hata, Kerstin W Sinkevicius, Dwight V Nissley, Eli M Wallace, Frank McCormick, Pedro J Beltran

Zitieren

APA

Simanshu, D. K., Xu, R., Stice, J. P., Czyzyk, D. J., Feng, S., Denson, J. P., Riegler, E., Yang, Y., Zhang, C., Donovan, S., Smith, B. P., Abreu-Blanco, M., Chen, M., Feng, C., Fu, L., Rabara, D., Young, L. C., Dyba, M., Yan, W., …, & Beltran, P. J. (2025). BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction. Science, 389(6758), 409-415. https://doi.org/10.1126/science.adq2004

Vancouver

Simanshu DK, Xu R, Stice JP, Czyzyk DJ, Feng S, Denson JP, et al. BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction. Science. 2025;389(6758):409-415. doi:10.1126/science.adq2004

BibTeX
@article{Simanshu2025,
  author = {Simanshu, Dhirendra K and Xu, Rui and Stice, James P and Czyzyk, Daniel J and Feng, Siyu and Denson, John-Paul and Riegler, Erin and Yang, Yue and Zhang, Cathy and Donovan, Sofia and Smith, Brian P and Abreu-Blanco, Maria and Chen, Ming and Feng, Cindy and Fu, Lijuan and Rabara, Dana and Young, Lucy C and Dyba, Marcin and Yan, Wupeng and Lin, Ken and Ghorbanpoorvalukolaie, Samar and Larsen, Erik K and Malik, Wafa and Champagne, Allison and Parker, Katie and Ju, Jin Hyun and Jeknic, Stevan and Esposito, Dominic and Turner, David M and Lightstone, Felice C and Wang, Bin and Wehn, Paul M and Wang, Keshi and Stephen, Andrew G and Maciag, Anna E and Hata, Aaron N and Sinkevicius, Kerstin W and Nissley, Dwight V and Wallace, Eli M and McCormick, Frank and Beltran, Pedro J},
  title = {BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction},
  journal = {Science},
  year = {2025},
  volume = {389},
  number = {6758},
  pages = {409--415},
  doi = {10.1126/science.adq2004}
}
Kostenlos starten →